Epigenomic Promoter Profiling for Gastric Cancer Detection and Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for studying promoter alterations in gastric cancer (GC) are limited to a gene-by-gene basis, lacking comprehensive understanding of global promoter-level diversity, which hinders the identification of new biomarkers for disease detection, prognosis, and therapeutic modalities.
Innovation Solution
A method involving the use of antibodies specific for histone modifications H3K4me3 and H3K4me1 to isolate nucleic acid with a signal ratio greater than 1, detecting signal intensity changes to determine the presence or absence of promoters, and employing EZH2 inhibitors to modulate promoter activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If promoter alterations are studied on a gene-by-gene basis, then detailed information about individual promoters can be obtained, but comprehensive understanding of global promoter-level diversity is lost
Solution Approach 1:
The patent combines multiple ChIP-seq experiments targeting different histone modifications (H3K4me3, H3K4me1, H3K27ac) into a unified analytical framework. This merging approach enables simultaneous assessment of multiple promoter states across the entire genome, resolving the contradiction by achieving both detailed individual promoter characterization and comprehensive global promoter diversity understanding through integrated multi-layer epigenomic data analysis
2Reliability
If conventional ChIP-seq methods are used for promoter profiling, then standard histone modification detection can be performed, but sensitivity and resolution for detecting subtle promoter changes in cancer are insufficient
Solution Approach 1:
The patent applies parameter changes by implementing replicates (biological and technical), optimizing sequencing depth, and using normalized signal ratios instead of absolute signal intensities. These parameter modifications enhance the sensitivity and precision of detecting subtle promoter changes in cancer samples while maintaining reliability through standardized protocols and quality control measures
3Loss of information
If comprehensive epigenomic profiling is performed across the entire genome, then global promoter landscape can be revealed, but complexity and cost of the methodology increase
Solution Approach 1:
The patent employs a universal ChIP-seq methodology that can detect multiple types of promoter elements (canonical, alternative, novel) using the same experimental platform and analytical pipeline. This multi-functional approach reveals the global promoter landscape without requiring separate specialized methods for each promoter type, thereby reducing overall complexity while maintaining comprehensive coverage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables comprehensive profiling of promoter elements in gastric cancer, providing biomarkers for detection and prognosis, and modulating promoter activity for therapeutic intervention.
Implementation Method 1
contacting the cancerous biological sample with at least one antibody specific for histone modifications H3K4me3 and H3K4me1
Data Source
AI summary
The present invention relates to a method for determining the presence or absence of at least one promoter in a cancerous biological sample relative to a non-cancerous biological sample. The present invention also relates to a method for determining the prognosis of cancer in a subject, a method for modulating the activity of at least one cancer-associated promoter in a cell, a method for modulating the immune response of a subject to cancer, a method for determining the presence of at least one cancer-associated promoter in a cancerous biological sample relative to a non-cancerous biological sample and a biomarker for detecting cancer in a subject.